At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating MK-3475, Carboplatin, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 91 participants across 11 sites.
Detailed Summary
This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall response rate (ORR) compared to MK-3475 administered before chemotherapy. Patients will be given Pembrolizumab as maintenance up to 2 years: Carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by pembrolizumab every 3 weeks for up to 2 years. Pembrolizumab every 3 weeks x 4 cycles followed by carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by pembrolizumab every 3 weeks for up to 2 years.
Study Details
Timeline
Interventions
Dose frequency of Q3W, Day 1 of each cycle
Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)